CYCLOSPORINE-A - CLINICAL-EXPERIENCE AND THERAPEUTIC DRUG-MONITORING

被引：31

作者：

LINDHOLM, A ^{[1
]}

机构：

[1] KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN

来源：

THERAPEUTIC DRUG MONITORING | 1995年 / 17卷 / 06期

关键词：

CYCLOSPORINE A; AREA-UNDER-THE-CURVE MONITORING;

D O I：

10.1097/00007691-199512000-00015

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

This article updates current studies on the concentration-effect relationship for cyclosporine A using specific analytical methodology in whole blood. Most of the existing documentation concerns renal transplantation. Trough level monitoring is recommended as the standard monitoring technique. However, there is a need to compare trough level monitoring with monitoring of the area-under-the-concentration-versus-time curve in prospective controlled trials. Further, there is a continuous need to update the concentration-effect relationship when introducing new immunosuppressive drug regimens.

引用

页码：631 / 637

页数：7

共 46 条

[1]

Keown P.A., Ulan R.A., Wall W.J., Et al., Immunological and pharmacological monitoring in the clinical use of cyclosporin A, Lancet, 1, pp. 686-689, (1981)

[2]

Shaw L.M., Bowers L., Demers L., Et al., Critical issues in cyclosporine monitoring: Report of the Task Force on Cy-closporine Monitoring, Clin Chem, 33, pp. 1269-1288, (1987)

[3]

Rodighiero V., Therapeutic drug monitoring of cyclosporine. Practical applications and limitations, Clin Pharmacokinet, 16, pp. 27-37, (1989)

[4]

Mc Millan M.A., Clinical pharmacokinetics of cyclosporin, Pharmacol Ther, 42, pp. 135-136, (1989)

[5]

Fahr A., Cyclosporin clinical pharmacokinetics, Clin Pharmacokinet, 24, pp. 472-495, (1993)

[6]

Lindholm A., Factors influencing the pharmacokinetics of cyclosporine, Ther Drug Monit, 13, pp. 465-477, (1991)

[7]

Lindholm A., Therapeutic monitoring of cyclosporin—an update, Eur J Clin Pharmacol, 41, pp. 273-283, (1991)

[8]

Shaw L.M., Yatscoff R.W., Bowers L.D., Et al., Canadian consensus meeting on cyclosporine monitoring: Report of the consensus panel, Clin Chem, 36, pp. 1841-1846, (1990)

[9]

Kahan B.D., Shaw L.M., Hold D., Grevel J., Johnston A., Consensus document: Hawk’s Cay meeting on therapeutic drug monitoring of cyclosporine, Clin Chem, 36, pp. 1510-1516, (1990)

[10]

Bunjes D., Hardt C., Rollinghoff M., Wagner H., Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2, Eur J Immunol, 11, pp. 657-661, (1989)

← 1 2 3 4 5 →